COMP <GO>
RYTM vs IONS // ALTMAN Z-SCORE & DEBT/EQUITY
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. Ionis Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RYTM 5
— IONS 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RYTM
LAST: $93.44 (+0.94%) • MKT CAP: $6.43B
balance-sheet
14.33
LAST: $41.24 (-5.24%) • MKT CAP: $6.85B
balance-sheet
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. IONS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | IONS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | 96.00% | -6.30 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | -20.90% | -8.70 | IONS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.82% | -4.34% | +2.52 | RYTM | /fcf-yield <GO> |
| Operating Margin | -60.00% | -40.40% | -19.60 | IONS | /operating-margins <GO> |
| Net Profit Margin | -0.10% | -40.40% | +40.30 | RYTM | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 33.80% | +12.00 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 14.33 | 1.08 | +13.25 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.8 | 36.2 | +16.60 | RYTM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.09 | -0.13 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 22.0x | +11.00 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.43B | $6.85B | -$419.9M | IONS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | IONS REV | RYTM GROSS % | IONS GROSS % | RYTM FCF | IONS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $943.7M | 89.7% | 98.3% | -$116.6M | -$320.0M |
| FY 2024 | $130.1M | $705.1M | 89.7% | 98.4% | -$113.9M | -$546.2M |
| FY 2023 | $77.4M | $787.6M | — | — | -$139.6M | -$343.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
IONS // BETA 1.09